38 GHP Q3 2025 SICGEN Antibodies (SICGEN) is a Portuguese biotechnology company founded in 2008 by scientists for scientists to produce and distribute high-quality polyclonal antibodies for research in cell and molecular biology. In light of being named Best Custom Polyclonal Antibody Production Company 2025, we learn more about SICGEN’s brilliant work, underscored by scientific excellence, reproducibility, and outstanding customer support. The SICGEN Antibodies team are true specialists in the world of polyclonal antibodies. They leverage a combined 20 years’ experience in scientific and technical expertise to offer personalised antibody production services, working closely with researcher clients to develop project-specific solutions that meet their exact needs. SICGEN places significant emphasis on antibody validation and reproducibility, aligning with global scientific standards and responding to the reproducibility crisis in research. This is while maintaining close ties with the academic community to ensure its products meet the expectations of high-level research. Guiding the team to achieve the company’s mission each day are a set of core values: Scientific Integrity, striving to uphold the highest standards of scientific rigor, transparency, and ethical responsibility in antibody development and validation; Quality and Reproducibility, with commitment to producing antibodies that provide consistent, reliable results across all experiments and applications; Innovation, working relentlessly to improve technologies and methods to fulfil emerging trends in cell and molecular biology research; Customer Focus, where, unlike larger corporations, they are dedicated to providing direct, tailored support to researchers, ensuring their needs and challenges are always understood and addressed, whether by delivering guidance in antibody selection, application protocols, or technical troubleshooting; Collaboration, working closely with academic and industrial partners to enhance product relevance and scientific impact; and Sustainability and Responsibility, promoting responsible use of resources and ethical practices in antibody production, including prioritising animal welfare and minimal environmental impact. “SICGEN stands out in the antibody industry through a combination of scientific specialisation, quality-driven production, and customeroriented practices.” Polyclonal Antibodies for Research in Life Sciences May25315 Some of SICGEN’s most notable product offerings include, of course, its polyclonal antibodies, which target a wide array of proteins, such as transcription factors, signalling molecules, membrane proteins, and exosomerelated markers, being suitable for applications inclusive of western blotting, immunofluorescence, immunohistochemistry, and ELISA. SICGEN also focuses on producing antibodies that aren’t widely available from other suppliers, including those for understudied or “missing” proteins. This is in addition to fluorescent-conjugated antibodies, which are ready-to-use antibodies labelled with fluorophores for direct detection in imaging applications. From there, the company goes on to offer specialised services in the form of custom antibody production, which is an end-to-end service extending from antigen design and synthesis to immunisation, purification, and validation. This is available for academic labs and biotech companies requiring exclusive antibodies for specific research targets. By utilising SICGEN’s services, clients benefit from high-quality, well-validated polyclonal antibodies, meaning reliable research results, which is crucial for publishing and progressing their research. Furthermore, partnering with SICGEN means researchers can save time by no longer performing in-house antibody development and reduce costs that are associated with poor-performing reagents. This is all while knowing that working with SICGEN supports responsible science, with its dedication to ethical production practices and sustainable research. The most credible and impactful testimonials for SICGEN are a numerous peer-reviewed scientific papers that cite the use of its antibodies. SICGEN looks to continue disrupting and innovating within the antibody research industry. It is aiming to become the go-to “missing” antibodies supplier, the plan being to launch a Rare Targets Initiative in collaboration with academic labs and incentivise researchers to co-develop antibodies for proteins with no current commercial coverage, for example, those based on Human Protein Atlas gaps or Orphanet gene targets, and offer free or discounted custom antibody production for publication-linked projects. The company is also working to develop its digital transformation and open science integration, to design an online antibody validation portal with side-by-side application results, user-submitted data, and protocol tips. This is while further accelerating its innovation through collaboration with emerging biotech and academic groups; scaling up its global reach while maintaining its agile, human-centred service; and, ultimately, becoming a leader in ethical antibody production. Company name: SICGEN Antibodies Contact name: José Ramalho Website: www.sicgen.pt
RkJQdWJsaXNoZXIy MTUyMDQwMA==